Cutler Group LP Relmada Therapeutics, Inc. Transaction History

Cutler Group LP

$307 Million
Q1 2024

A detailed history of Cutler Group LP transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Cutler Group LP holds 9,000 shares of RLMD stock, worth $5,310. This represents 0.01% of its overall portfolio holdings.

Number of Shares

9,000

Previous 9,300 3.23%

Holding current value

$5,310

Previous $38,000 7.89%

% of portfolio

0.01%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 19, 2024	SELL	$3.1 - $6.8 $930 - $2,040	-300 Reduced 3.23%	9,000 $41,000
Q1 2023 May 01, 2023	SELL	$2.24 - $4.76 $33,824 - $71,876	-15,100 Reduced 61.89%	9,300 $21,000
Q4 2022 Feb 07, 2023	BUY	$2.17 - $35.84 $30,202 - $498,821	13,918 Added 132.78%	24,400 $85,000
Q3 2022 Oct 25, 2022	BUY	$18.3 - $37.02 $143,014 - $289,311	7,815 Added 293.03%	10,482 $388,000
Q2 2022 Aug 04, 2022	SELL	$16.5 - $30.34 $116,803 - $214,776	-7,079 Reduced 72.63%	2,667 $50,000
Q1 2022 Apr 14, 2022	BUY	$16.72 - $26.99 $159,609 - $257,646	9,546 Added 4773.0%	9,746 $263,000
Q4 2021 Jan 18, 2022	SELL	$16.93 - $26.82 $23,702 - $37,548	-1,400 Reduced 87.5%	200 $4,000
Q3 2021 Oct 26, 2021	BUY	$21.86 - $34.77 $8,744 - $13,908	400 Added 33.33%	1,600 $41,000
Q2 2021 Jul 19, 2021	BUY	$29.55 - $39.15 $14,775 - $19,575	500 Added 71.43%	1,200 $38,000
Q1 2021 Apr 26, 2021	BUY	$31.52 - $39.28 $17,020 - $21,211	540 Added 337.5%	700 $24,000
Q4 2020 Jan 21, 2021	SELL	$29.88 - $39.8 $1,195 - $1,592	-40 Reduced 20.0%	160 $5,000
Q3 2020 Oct 27, 2020	SELL	$34.42 - $43.78 $24,094 - $30,646	-700 Reduced 77.78%	200 $7,000
Q1 2020 May 07, 2020	BUY	$23.78 - $50.12 $21,402 - $45,108	900 New	900 $30,000

Others Institutions Holding RLMD

# of Institutions

Shares Held

5.82M

Call Options Held

Put Options Held

View Full List

About RELMADA THERAPEUTICS, INC.

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $16.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

More about RLMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

News

Stay updated on Cutler Group LP with notifications on news.

Account